Business
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
World Renowned Cardiologist and Research Leader to Guide Clinical Strategy, Product Innovation, and AI-Driven Cardiac Diagnostics TORONTO, ON / ACCESS Newswire / January 28, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) ...
About this update from Aiml Innovations Inc
[{"type":"list","items":[{"val":[{"type":"text","content":"World Renowned Cardiologist and Research Leader to Guide Clinical Strategy, Product Innovation, and AI-Driven Cardiac Diagnostics","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":129,"olType":false},{"type":"text","content":"TORONTO, ON / ACCESS Newswire / January 28, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Paul Dorian, MD, MSc., as the Company's Medical Innovation Architect (MIA) and Head of the Company's Medical Advisory Board, effective immediately.","length":355,"tagName":"p"},{"type":"text","content":"Dr. Dorian succeeds Peter Kendall, who previously served as Chair of the Medical Advisory Board. This leadership transition comes as AIML enters a phase of advanced clinical validation, regulatory engagement, and global deployment of its AI-powered cardiac diagnostic technologies.","length":281,"tagName":"p"},{"type":"text","content":"Dr. Dorian has been working closely with AIML for several months, contributing to product strategy, clinical positioning, and innovation initiatives across the Company's MaxYield™,CardioYield™, and Insight360™ platforms. His formal appointment further strengthens the clinical leadership underpinning AIML's next phase of growth.","length":337,"tagName":"p"},{"type":"text","content":"Dr. Paul Dorian commented: "I have been impressed by the rigor of AIML's science and the ambition of its vision. The Company is addressing real, unmet needs in cardiac diagnostics by combining advanced AI with practical, scalable clinical solutions. I look forward to helping guide innovation, clinical strategy, and the translation of AIML's technology into clinically meaningful impact."","length":407,"tagName":"p"},{"type":"text","content":""Dr. Dorian's appointment marks a pivotal milestone for AIML," said Paul Duffy, Executive Chairman and CEO of AIML. "He brings unparalleled expertise in cardiac electrophysiology, clinical research, and health-system innovation. As we expand into regulated clinical markets and large-scale deployments, his leadership will help ensure our technology meets the highest standards of clinical relevance, safety, and impact."","length":445,"tagName":"p"},{"type"...